Anurag

Anurag Bagaria is the Chairman & CEO of Kemwell Biopharma, one of India’s largest biopharmaceutical CDMO providing customized process development, product development and manufacturing solutions for biologics and cell therapies to global biopharmaceutical companies. Anurag joined Kemwell in 2004 as a second-generation entrepreneur and became Chairman in 2010. He expanded Kemwell’s facilities in India, Sweden and the U.S., providing CDMO services for small and large molecule drugs for global markets. In 2017, he led the sale of Kemwell’s small-molecule services business to Recipharm AB.

Anurag also serves on the Board of Stempeutics, a company developing stem-cell based therapeutics, ProLynx Inc., a company developing products based on their half-life extension technology platform, among other drug-development startups that he is actively involved with.

Anurag holds a degree in Chemical Engineering from Cornell University and an MBA from the Kellogg School of Management.

• Over 20 Years of Experience, second generation entrepreneur
• Pharma business built to 100+ Million USD and currently leading Kemwell’s biopharma business
• MBA from Kellogg Business School and BS in Chemical Engineering, Cornell University